Skip to content

Study · Non-randomized trial · n = 62 · 2008

2 results

[New possibilities of neuroprotection in the treatment of ischemic stroke].

Skoromets AA, Stakhovskaia LV, Belkin AA, Shekhovtsova KV, Kerbikov OB, Burenchev DV, Gavrilova OV, Skvortsova VI

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2008

PMID19431244 (opens in a new tab)PepBankPUB-19431244
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with acute ischemic stroke, the results suggested cortexin efficacy compared with placebo.

    In plain wordsIn patients with acute ischemic stroke, the results suggested cortexin efficacy compared with placebo.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseOverall treatment efficacy
    Study

    n = 62

    Comparator
    placebo with basic treatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    20 mg daily · intramuscular · 10 daysAs given in this study (human).

    Source sentences

    Summary
    The data obtained suggest an efficacy of cortexin in the treatment of patients with acute ischemic stroke as compared to placebo.
    2 context sentences
    Summary · context
    A multicenter prospective double-blind placebo-controlled study was carried out in 62 patients with hemisphere ischemic stroke of atherothrombotic or cardiothrombotic character.
    Summary · context
    Thirty-two patients, a main group, received intramuscular injections of cortexin, a domestic drug, in dosage 20 mg daily during 10 days from the first 6 hours from the development of symptoms of stroke, and 30 patients, a control group, received basic treatment and intramuscular injections of placeb…
  2. 02HumanNon-randomized trialSafety outcome

    In patients with acute ischemic stroke, the study reported that cortexin safety was confirmed, without specific event data.

    In plain wordsIn patients with acute ischemic stroke, the study reported cortexin safety without specific event data.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Not applicableOverall safety
    Study

    n = 32

    Outcome group
    Adverse events · Whole body
    Studied dose
    20 mg daily · intramuscular · 10 daysAs given in this study (human).

    Source sentences

    Summary
    Safety of the drug was confirmed in the study.
    2 context sentences
    Summary · context
    A multicenter prospective double-blind placebo-controlled study was carried out in 62 patients with hemisphere ischemic stroke of atherothrombotic or cardiothrombotic character.
    Summary · context
    Thirty-two patients, a main group, received intramuscular injections of cortexin, a domestic drug, in dosage 20 mg daily during 10 days from the first 6 hours from the development of symptoms of stroke, and 30 patients, a control group, received basic treatment and intramuscular injections of placeb…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.